Parkinson’s Disease Registry of the Muhammad Ali Parkinson Center
The purpose of the Parkinson’s disease Registry is to develop a national and international database of persons with Parkinson’s disease (PD). The Registry will be used to facilitate the development of new therapies and healthcare services to improve the quality of life for people with PD. It will also be a means for investigators in the field of PD to quickly identify and notify subjects about other research studies for which they are eligible.
- Assess current treatment approaches and develop best-practice guidelines
- Track the functional abilities, access to healthcare and cost of illness of people with PD over time
- Drive the development of innovative research projects
- Accelerate the process of informing patients of research projects for which they may be eligible
Clinical Effect of Ampreloxetine (TD-9855) for Treating snOH in Subjects with Primary Autonomic Failure
A Phase 3 study to evaluate efficacy, safety, and tolerability of ampreloxetine (TD-9855) in subjects with primary autonomic failures (MSA, PD, or PAF) and snOH with up to 4 weeks of treatment.
A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate efficacy, safety, and tolerability of ampreloxetine (TD-9855) in subjects with primary autonomic failures (MSA, PD, or PAF) and snOH. The study consists of 3 periods: (i) 2-week screening, (ii) 4-week randomized treatment, and (iii) 2-week follow up.
A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease
This is a multicenter, randomized, double-blind, placebo-controlled, three-arm parallel group study to evaluate the efficacy, safety, and pharmacokinetics (PK) of pridopidine versus placebo for the treatment of Levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease.
Troriluzole in Adult Subjects with Spinocerebellar Ataxia
The purpose of this study is to compare the efficacy of Troriluzole (200mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).